FDA: Increased HBV reactivation risk with ofatumumab or rituximab

JAMA. 2013 Oct 23;310(16):1664. doi: 10.1001/jama.2013.281115.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Hepatitis B / immunology
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / immunology
  • Humans
  • Immunologic Factors / adverse effects*
  • Risk
  • Rituximab
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunologic Factors
  • Rituximab
  • ofatumumab